Cargando…
The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma
Immune checkpoint modulation in cancer has been demonstrated as a high-value therapeutic strategy in many tumor entities. VISTA is an immune checkpoint receptor regulating T-cell function. To the best of our knowledge, nothing is known about the expression and prognostic impact of VISTA on tumor inf...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492979/ https://www.ncbi.nlm.nih.gov/pubmed/31069143 http://dx.doi.org/10.1080/2162402X.2019.1581546 |
_version_ | 1783415173015404544 |
---|---|
author | Loeser, Heike Kraemer, Max Gebauer, Florian Bruns, Christiane Schröder, Wolfgang Zander, Thomas Persa, Oana-Diana Alakus, Hakan Hoelscher, Arnulf Buettner, Reinhard Lohneis, Philipp Quaas, Alexander |
author_facet | Loeser, Heike Kraemer, Max Gebauer, Florian Bruns, Christiane Schröder, Wolfgang Zander, Thomas Persa, Oana-Diana Alakus, Hakan Hoelscher, Arnulf Buettner, Reinhard Lohneis, Philipp Quaas, Alexander |
author_sort | Loeser, Heike |
collection | PubMed |
description | Immune checkpoint modulation in cancer has been demonstrated as a high-value therapeutic strategy in many tumor entities. VISTA is an immune checkpoint receptor regulating T-cell function. To the best of our knowledge, nothing is known about the expression and prognostic impact of VISTA on tumor infiltrating lymphocytes (TILs) in the tumor microenvironment of esophageal adenocarcinoma (EAC). We analyzed in total 393 EACs within a test-cohort (n = 165) and a validation-cohort (n = 228) using a monoclonal antibody (clone D1L2G). These data were statistically correlated with clinical as well as molecular data. 22.2% of the tumor cohort presented with a VISTA expression on TILs. These patients demonstrated an improved median overall survival compared to patients without VISTA expression (202.2 months vs. 21.6 months; p < 0.0001). The favorable outcome of VISTA positive tumors is significant in the entire cohort but mainly driven by the general better prognosis of T1/T2 tumors. However, in the pT1/2 group, VISTA positive tumors show a tremendous survival benefit compared to VISTA negative tumors revealing real long-term survivors in this particular subgroup. The survival difference is independent of the T-stage. This unique characteristic could influence neoadjuvant therapy concepts for EAC, since a profit of therapy could be reduced in the already favorable subgroup of VISTA positive tumors. VISTA emerges as a prognostic biomarker for long-term survival especially in the group of early TNM-stages. Future studies have to show the relevance of VISTA positive TILs within a tumor concerning response to specific immune checkpoint inhibition. |
format | Online Article Text |
id | pubmed-6492979 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-64929792019-05-08 The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma Loeser, Heike Kraemer, Max Gebauer, Florian Bruns, Christiane Schröder, Wolfgang Zander, Thomas Persa, Oana-Diana Alakus, Hakan Hoelscher, Arnulf Buettner, Reinhard Lohneis, Philipp Quaas, Alexander Oncoimmunology Original Research Immune checkpoint modulation in cancer has been demonstrated as a high-value therapeutic strategy in many tumor entities. VISTA is an immune checkpoint receptor regulating T-cell function. To the best of our knowledge, nothing is known about the expression and prognostic impact of VISTA on tumor infiltrating lymphocytes (TILs) in the tumor microenvironment of esophageal adenocarcinoma (EAC). We analyzed in total 393 EACs within a test-cohort (n = 165) and a validation-cohort (n = 228) using a monoclonal antibody (clone D1L2G). These data were statistically correlated with clinical as well as molecular data. 22.2% of the tumor cohort presented with a VISTA expression on TILs. These patients demonstrated an improved median overall survival compared to patients without VISTA expression (202.2 months vs. 21.6 months; p < 0.0001). The favorable outcome of VISTA positive tumors is significant in the entire cohort but mainly driven by the general better prognosis of T1/T2 tumors. However, in the pT1/2 group, VISTA positive tumors show a tremendous survival benefit compared to VISTA negative tumors revealing real long-term survivors in this particular subgroup. The survival difference is independent of the T-stage. This unique characteristic could influence neoadjuvant therapy concepts for EAC, since a profit of therapy could be reduced in the already favorable subgroup of VISTA positive tumors. VISTA emerges as a prognostic biomarker for long-term survival especially in the group of early TNM-stages. Future studies have to show the relevance of VISTA positive TILs within a tumor concerning response to specific immune checkpoint inhibition. Taylor & Francis 2019-02-27 /pmc/articles/PMC6492979/ /pubmed/31069143 http://dx.doi.org/10.1080/2162402X.2019.1581546 Text en © 2019 The Author(s). Published with license by Taylor & Francis Group, LLC. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. |
spellingShingle | Original Research Loeser, Heike Kraemer, Max Gebauer, Florian Bruns, Christiane Schröder, Wolfgang Zander, Thomas Persa, Oana-Diana Alakus, Hakan Hoelscher, Arnulf Buettner, Reinhard Lohneis, Philipp Quaas, Alexander The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma |
title | The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma |
title_full | The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma |
title_fullStr | The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma |
title_full_unstemmed | The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma |
title_short | The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma |
title_sort | expression of the immune checkpoint regulator vista correlates with improved overall survival in pt1/2 tumor stages in esophageal adenocarcinoma |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492979/ https://www.ncbi.nlm.nih.gov/pubmed/31069143 http://dx.doi.org/10.1080/2162402X.2019.1581546 |
work_keys_str_mv | AT loeserheike theexpressionoftheimmunecheckpointregulatorvistacorrelateswithimprovedoverallsurvivalinpt12tumorstagesinesophagealadenocarcinoma AT kraemermax theexpressionoftheimmunecheckpointregulatorvistacorrelateswithimprovedoverallsurvivalinpt12tumorstagesinesophagealadenocarcinoma AT gebauerflorian theexpressionoftheimmunecheckpointregulatorvistacorrelateswithimprovedoverallsurvivalinpt12tumorstagesinesophagealadenocarcinoma AT brunschristiane theexpressionoftheimmunecheckpointregulatorvistacorrelateswithimprovedoverallsurvivalinpt12tumorstagesinesophagealadenocarcinoma AT schroderwolfgang theexpressionoftheimmunecheckpointregulatorvistacorrelateswithimprovedoverallsurvivalinpt12tumorstagesinesophagealadenocarcinoma AT zanderthomas theexpressionoftheimmunecheckpointregulatorvistacorrelateswithimprovedoverallsurvivalinpt12tumorstagesinesophagealadenocarcinoma AT persaoanadiana theexpressionoftheimmunecheckpointregulatorvistacorrelateswithimprovedoverallsurvivalinpt12tumorstagesinesophagealadenocarcinoma AT alakushakan theexpressionoftheimmunecheckpointregulatorvistacorrelateswithimprovedoverallsurvivalinpt12tumorstagesinesophagealadenocarcinoma AT hoelscherarnulf theexpressionoftheimmunecheckpointregulatorvistacorrelateswithimprovedoverallsurvivalinpt12tumorstagesinesophagealadenocarcinoma AT buettnerreinhard theexpressionoftheimmunecheckpointregulatorvistacorrelateswithimprovedoverallsurvivalinpt12tumorstagesinesophagealadenocarcinoma AT lohneisphilipp theexpressionoftheimmunecheckpointregulatorvistacorrelateswithimprovedoverallsurvivalinpt12tumorstagesinesophagealadenocarcinoma AT quaasalexander theexpressionoftheimmunecheckpointregulatorvistacorrelateswithimprovedoverallsurvivalinpt12tumorstagesinesophagealadenocarcinoma AT loeserheike expressionoftheimmunecheckpointregulatorvistacorrelateswithimprovedoverallsurvivalinpt12tumorstagesinesophagealadenocarcinoma AT kraemermax expressionoftheimmunecheckpointregulatorvistacorrelateswithimprovedoverallsurvivalinpt12tumorstagesinesophagealadenocarcinoma AT gebauerflorian expressionoftheimmunecheckpointregulatorvistacorrelateswithimprovedoverallsurvivalinpt12tumorstagesinesophagealadenocarcinoma AT brunschristiane expressionoftheimmunecheckpointregulatorvistacorrelateswithimprovedoverallsurvivalinpt12tumorstagesinesophagealadenocarcinoma AT schroderwolfgang expressionoftheimmunecheckpointregulatorvistacorrelateswithimprovedoverallsurvivalinpt12tumorstagesinesophagealadenocarcinoma AT zanderthomas expressionoftheimmunecheckpointregulatorvistacorrelateswithimprovedoverallsurvivalinpt12tumorstagesinesophagealadenocarcinoma AT persaoanadiana expressionoftheimmunecheckpointregulatorvistacorrelateswithimprovedoverallsurvivalinpt12tumorstagesinesophagealadenocarcinoma AT alakushakan expressionoftheimmunecheckpointregulatorvistacorrelateswithimprovedoverallsurvivalinpt12tumorstagesinesophagealadenocarcinoma AT hoelscherarnulf expressionoftheimmunecheckpointregulatorvistacorrelateswithimprovedoverallsurvivalinpt12tumorstagesinesophagealadenocarcinoma AT buettnerreinhard expressionoftheimmunecheckpointregulatorvistacorrelateswithimprovedoverallsurvivalinpt12tumorstagesinesophagealadenocarcinoma AT lohneisphilipp expressionoftheimmunecheckpointregulatorvistacorrelateswithimprovedoverallsurvivalinpt12tumorstagesinesophagealadenocarcinoma AT quaasalexander expressionoftheimmunecheckpointregulatorvistacorrelateswithimprovedoverallsurvivalinpt12tumorstagesinesophagealadenocarcinoma |